{"text":"The other received chemotherapy including prednisone , vincristine , cytarabine and L-asparaginase , combined with intrathecal injections of methotrexate , dexamethasone and Ara-C and supporting treatment .","paragraph":"<h3><u>[Renal tubular acidosis as an initial manifestation in children with malignant lymphoma].</u></h3>Primary renal lymphoma is one of the malignant lymphomas that initially presents in the extra lymphonode, which is rarely seen in children. This study reported two cases of primary renal lymphoma in children who were definitively diagnosed by renal biopsy. Renal tubular acidosis was the initial manifestation in both cases. They were referred to the hospital with chief complaints of polydipsia, polyuria, debilitation, vomiting and anemia. Imaging and laboratory examinations showed bilateral renomegaly, hypocalcemia, hypophosphatemia, and metabolic acidosis. One of the patients discontinued therapy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>L-asparaginase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>injections</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Ara-C</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>supporting</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-three days after treatment, polydipsia and polyuria were relieved, and acidosis, kaliopenia and anemia were improved in the patient. There were no abnormal findings in the renal B-ultrasound re-examination. It was concluded that when a patient is suspected of renal lymphoma, diagnostic puncture and renal biopsy should be performed early. Early combined therapeutics including chemotherapy, radiation therapy, surgery and supporting treatments may result in a favorable prognosis in patients with this disease.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"other","start":4,"end":9,"id":1,"ws":true},{"text":"received","start":10,"end":18,"id":2,"ws":true},{"text":"chemotherapy","start":19,"end":31,"id":3,"ws":true},{"text":"including","start":32,"end":41,"id":4,"ws":true},{"text":"prednisone","start":42,"end":52,"id":5,"ws":true},{"text":",","start":53,"end":54,"id":6,"ws":true},{"text":"vincristine","start":55,"end":66,"id":7,"ws":true},{"text":",","start":67,"end":68,"id":8,"ws":true},{"text":"cytarabine","start":69,"end":79,"id":9,"ws":true},{"text":"and","start":80,"end":83,"id":10,"ws":true},{"text":"L-asparaginase","start":84,"end":98,"id":11,"ws":true},{"text":",","start":99,"end":100,"id":12,"ws":true},{"text":"combined","start":101,"end":109,"id":13,"ws":true},{"text":"with","start":110,"end":114,"id":14,"ws":true},{"text":"intrathecal","start":115,"end":126,"id":15,"ws":true},{"text":"injections","start":127,"end":137,"id":16,"ws":true},{"text":"of","start":138,"end":140,"id":17,"ws":true},{"text":"methotrexate","start":141,"end":153,"id":18,"ws":true},{"text":",","start":154,"end":155,"id":19,"ws":true},{"text":"dexamethasone","start":156,"end":169,"id":20,"ws":true},{"text":"and","start":170,"end":173,"id":21,"ws":true},{"text":"Ara-C","start":174,"end":179,"id":22,"ws":true},{"text":"and","start":180,"end":183,"id":23,"ws":true},{"text":"supporting","start":184,"end":194,"id":24,"ws":true},{"text":"treatment","start":195,"end":204,"id":25,"ws":true},{"text":".","start":205,"end":206,"id":26,"ws":false}],"spans":[{"start":42,"end":52,"token_start":5,"token_end":5,"label":"DRUG"},{"start":55,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},{"start":69,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":84,"end":98,"token_start":11,"token_end":11,"label":"DRUG"},{"start":141,"end":153,"token_start":18,"token_end":18,"label":"DRUG"},{"start":156,"end":169,"token_start":20,"token_end":20,"label":"DRUG"},{"start":174,"end":179,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18706173/","_input_hash":179949336,"_task_hash":667588676,"_session_id":"drug_drug_pilot2_yakir-yakir","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":42,"end":52,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":55,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":7,"child":9,"head_span":{"start":55,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":69,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":69,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":84,"end":98,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":18,"head_span":{"start":84,"end":98,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":141,"end":153,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":20,"head_span":{"start":141,"end":153,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":156,"end":169,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":22,"head_span":{"start":156,"end":169,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":174,"end":179,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The other received chemotherapy including prednisone , vincristine , cytarabine and L-asparaginase , combined with intrathecal injections of methotrexate , dexamethasone and Ara-C and supporting treatment .","paragraph":"<h3><u>[Renal tubular acidosis as an initial manifestation in children with malignant lymphoma].</u></h3>Primary renal lymphoma is one of the malignant lymphomas that initially presents in the extra lymphonode, which is rarely seen in children. This study reported two cases of primary renal lymphoma in children who were definitively diagnosed by renal biopsy. Renal tubular acidosis was the initial manifestation in both cases. They were referred to the hospital with chief complaints of polydipsia, polyuria, debilitation, vomiting and anemia. Imaging and laboratory examinations showed bilateral renomegaly, hypocalcemia, hypophosphatemia, and metabolic acidosis. One of the patients discontinued therapy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>L-asparaginase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>injections</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Ara-C</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>supporting</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-three days after treatment, polydipsia and polyuria were relieved, and acidosis, kaliopenia and anemia were improved in the patient. There were no abnormal findings in the renal B-ultrasound re-examination. It was concluded that when a patient is suspected of renal lymphoma, diagnostic puncture and renal biopsy should be performed early. Early combined therapeutics including chemotherapy, radiation therapy, surgery and supporting treatments may result in a favorable prognosis in patients with this disease.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"other","start":4,"end":9,"id":1,"ws":true},{"text":"received","start":10,"end":18,"id":2,"ws":true},{"text":"chemotherapy","start":19,"end":31,"id":3,"ws":true},{"text":"including","start":32,"end":41,"id":4,"ws":true},{"text":"prednisone","start":42,"end":52,"id":5,"ws":true},{"text":",","start":53,"end":54,"id":6,"ws":true},{"text":"vincristine","start":55,"end":66,"id":7,"ws":true},{"text":",","start":67,"end":68,"id":8,"ws":true},{"text":"cytarabine","start":69,"end":79,"id":9,"ws":true},{"text":"and","start":80,"end":83,"id":10,"ws":true},{"text":"L-asparaginase","start":84,"end":98,"id":11,"ws":true},{"text":",","start":99,"end":100,"id":12,"ws":true},{"text":"combined","start":101,"end":109,"id":13,"ws":true},{"text":"with","start":110,"end":114,"id":14,"ws":true},{"text":"intrathecal","start":115,"end":126,"id":15,"ws":true},{"text":"injections","start":127,"end":137,"id":16,"ws":true},{"text":"of","start":138,"end":140,"id":17,"ws":true},{"text":"methotrexate","start":141,"end":153,"id":18,"ws":true},{"text":",","start":154,"end":155,"id":19,"ws":true},{"text":"dexamethasone","start":156,"end":169,"id":20,"ws":true},{"text":"and","start":170,"end":173,"id":21,"ws":true},{"text":"Ara-C","start":174,"end":179,"id":22,"ws":true},{"text":"and","start":180,"end":183,"id":23,"ws":true},{"text":"supporting","start":184,"end":194,"id":24,"ws":true},{"text":"treatment","start":195,"end":204,"id":25,"ws":true},{"text":".","start":205,"end":206,"id":26,"ws":false}],"spans":[{"start":42,"end":52,"token_start":5,"token_end":5,"label":"DRUG"},{"start":55,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},{"start":69,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":84,"end":98,"token_start":11,"token_end":11,"label":"DRUG"},{"start":141,"end":153,"token_start":18,"token_end":18,"label":"DRUG"},{"start":156,"end":169,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18706173/","_input_hash":179949336,"_task_hash":667588676,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":42,"end":52,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":55,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":7,"child":9,"head_span":{"start":55,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":69,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":69,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":84,"end":98,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Twenty-seven received rituximab mainly in addition to high-dose cytarabine and etoposide ( n = 18 ) and/or ifosfamide , carboplatin , and etoposide ( n = 7 ) .","paragraph":"<h3><u>Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.</u></h3>In order to describe relapsed B-cell non-Hodgkin lymphoma and mature acute leukemia in children/adolescents treated with the Lymphomes Malins B (LMB) regimen and their outcome in the <b style='color:Tomato;'><i>rituximab</i></b> era, relapses in the French LMB2001 study were reviewed. ### methods Between February 2001 and December 2011, 33 patients out of 773 (4.3%) relapsed; 27 had Burkitt lymphoma and six large B-cell histology. Median age at diagnosis was 10.1 years. One patient was initially treated in risk group A, 21 in group B, and 11 in group C. ### results Median time to relapse after diagnosis was 4.5 months (range 2.4-13.6). Thirty-two patients received salvage therapy. <b style='color:DodgerBlue;'><i>Twenty-seven</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>mainly</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> First-line salvage chemotherapy response rate was 66% with 47% being complete remission (CR). Twenty-one patients received high-dose chemotherapy (HDC) followed by autologous (n\u00a0=\u00a013) or allogeneic (n\u00a0=\u00a08) transplant. With a median follow-up of 6.8 years, the 5-year survival rate after relapse was 36.4% (95% confidence interval [CI] 22-53%). Twelve patients were still alive; all but one (group A) received consolidation treatment. Achieving CR before consolidation was significantly associated with better survival, with a 5-year survival rate of 75% (95% CI 46.8-91.1%) for patients in CR before HDC, 33% (95% CI 9.7-70%) for patients in partial remission, and 0% for nonresponders (P\u00a0=\u00a0.033). ### conclusion Survival of children/adolescents with mature B-cell lymphoma/leukemia remains poor after relapse with no apparent improvement with <b style='color:Tomato;'><i>rituximab</i></b>. Response rates to salvage chemo-immunotherapies are insufficient and new drugs are urgently needed to improve disease control.","tokens":[{"text":"Twenty-seven","start":0,"end":12,"id":0,"ws":true},{"text":"received","start":13,"end":21,"id":1,"ws":true},{"text":"rituximab","start":22,"end":31,"id":2,"ws":true},{"text":"mainly","start":32,"end":38,"id":3,"ws":true},{"text":"in","start":39,"end":41,"id":4,"ws":true},{"text":"addition","start":42,"end":50,"id":5,"ws":true},{"text":"to","start":51,"end":53,"id":6,"ws":true},{"text":"high-dose","start":54,"end":63,"id":7,"ws":true},{"text":"cytarabine","start":64,"end":74,"id":8,"ws":true},{"text":"and","start":75,"end":78,"id":9,"ws":true},{"text":"etoposide","start":79,"end":88,"id":10,"ws":true},{"text":"(","start":89,"end":90,"id":11,"ws":true},{"text":"n","start":91,"end":92,"id":12,"ws":true},{"text":"=","start":93,"end":94,"id":13,"ws":true},{"text":"18","start":95,"end":97,"id":14,"ws":true},{"text":")","start":98,"end":99,"id":15,"ws":true},{"text":"and/or","start":100,"end":106,"id":16,"ws":true},{"text":"ifosfamide","start":107,"end":117,"id":17,"ws":true},{"text":",","start":118,"end":119,"id":18,"ws":true},{"text":"carboplatin","start":120,"end":131,"id":19,"ws":true},{"text":",","start":132,"end":133,"id":20,"ws":true},{"text":"and","start":134,"end":137,"id":21,"ws":true},{"text":"etoposide","start":138,"end":147,"id":22,"ws":true},{"text":"(","start":148,"end":149,"id":23,"ws":true},{"text":"n","start":150,"end":151,"id":24,"ws":true},{"text":"=","start":152,"end":153,"id":25,"ws":true},{"text":"7","start":154,"end":155,"id":26,"ws":true},{"text":")","start":156,"end":157,"id":27,"ws":true},{"text":".","start":158,"end":159,"id":28,"ws":false}],"spans":[{"start":22,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},{"start":64,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},{"start":79,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},{"start":120,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},{"start":138,"end":147,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31207026/","_input_hash":1793273855,"_task_hash":1909897363,"_session_id":"drug_drug_pilot2_yakir-yakir","_view_id":"blocks","relations":[{"head":2,"child":8,"head_span":{"start":22,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":64,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":2,"child":10,"head_span":{"start":22,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":79,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":2,"child":8,"head_span":{"start":22,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":64,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":10,"child":2,"head_span":{"start":79,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":22,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":10,"child":17,"head_span":{"start":79,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":17,"child":19,"head_span":{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":120,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":2,"child":17,"head_span":{"start":22,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"},{"head":17,"child":19,"head_span":{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":120,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"},{"head":19,"child":22,"head_span":{"start":120,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":138,"end":147,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":[],"answer":"accept"}
{"text":"Twenty-seven received rituximab mainly in addition to high-dose cytarabine and etoposide ( n = 18 ) and/or ifosfamide , carboplatin , and etoposide ( n = 7 ) .","paragraph":"<h3><u>Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.</u></h3>In order to describe relapsed B-cell non-Hodgkin lymphoma and mature acute leukemia in children/adolescents treated with the Lymphomes Malins B (LMB) regimen and their outcome in the <b style='color:Tomato;'><i>rituximab</i></b> era, relapses in the French LMB2001 study were reviewed. ### methods Between February 2001 and December 2011, 33 patients out of 773 (4.3%) relapsed; 27 had Burkitt lymphoma and six large B-cell histology. Median age at diagnosis was 10.1 years. One patient was initially treated in risk group A, 21 in group B, and 11 in group C. ### results Median time to relapse after diagnosis was 4.5 months (range 2.4-13.6). Thirty-two patients received salvage therapy. <b style='color:DodgerBlue;'><i>Twenty-seven</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>mainly</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> First-line salvage chemotherapy response rate was 66% with 47% being complete remission (CR). Twenty-one patients received high-dose chemotherapy (HDC) followed by autologous (n\u00a0=\u00a013) or allogeneic (n\u00a0=\u00a08) transplant. With a median follow-up of 6.8 years, the 5-year survival rate after relapse was 36.4% (95% confidence interval [CI] 22-53%). Twelve patients were still alive; all but one (group A) received consolidation treatment. Achieving CR before consolidation was significantly associated with better survival, with a 5-year survival rate of 75% (95% CI 46.8-91.1%) for patients in CR before HDC, 33% (95% CI 9.7-70%) for patients in partial remission, and 0% for nonresponders (P\u00a0=\u00a0.033). ### conclusion Survival of children/adolescents with mature B-cell lymphoma/leukemia remains poor after relapse with no apparent improvement with <b style='color:Tomato;'><i>rituximab</i></b>. Response rates to salvage chemo-immunotherapies are insufficient and new drugs are urgently needed to improve disease control.","tokens":[{"text":"Twenty-seven","start":0,"end":12,"id":0,"ws":true},{"text":"received","start":13,"end":21,"id":1,"ws":true},{"text":"rituximab","start":22,"end":31,"id":2,"ws":true},{"text":"mainly","start":32,"end":38,"id":3,"ws":true},{"text":"in","start":39,"end":41,"id":4,"ws":true},{"text":"addition","start":42,"end":50,"id":5,"ws":true},{"text":"to","start":51,"end":53,"id":6,"ws":true},{"text":"high-dose","start":54,"end":63,"id":7,"ws":true},{"text":"cytarabine","start":64,"end":74,"id":8,"ws":true},{"text":"and","start":75,"end":78,"id":9,"ws":true},{"text":"etoposide","start":79,"end":88,"id":10,"ws":true},{"text":"(","start":89,"end":90,"id":11,"ws":true},{"text":"n","start":91,"end":92,"id":12,"ws":true},{"text":"=","start":93,"end":94,"id":13,"ws":true},{"text":"18","start":95,"end":97,"id":14,"ws":true},{"text":")","start":98,"end":99,"id":15,"ws":true},{"text":"and/or","start":100,"end":106,"id":16,"ws":true},{"text":"ifosfamide","start":107,"end":117,"id":17,"ws":true},{"text":",","start":118,"end":119,"id":18,"ws":true},{"text":"carboplatin","start":120,"end":131,"id":19,"ws":true},{"text":",","start":132,"end":133,"id":20,"ws":true},{"text":"and","start":134,"end":137,"id":21,"ws":true},{"text":"etoposide","start":138,"end":147,"id":22,"ws":true},{"text":"(","start":148,"end":149,"id":23,"ws":true},{"text":"n","start":150,"end":151,"id":24,"ws":true},{"text":"=","start":152,"end":153,"id":25,"ws":true},{"text":"7","start":154,"end":155,"id":26,"ws":true},{"text":")","start":156,"end":157,"id":27,"ws":true},{"text":".","start":158,"end":159,"id":28,"ws":false}],"spans":[{"start":22,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},{"start":64,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},{"start":79,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},{"start":120,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},{"start":138,"end":147,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31207026/","_input_hash":1793273855,"_task_hash":1909897363,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":2,"child":8,"head_span":{"start":22,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":64,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":10,"child":17,"head_span":{"start":79,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":19,"child":22,"head_span":{"start":120,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":138,"end":147,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":8,"child":10,"head_span":{"start":64,"end":74,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":79,"end":88,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":17,"child":19,"head_span":{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":120,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"In metastastic patients , the combination of gemcitabine and cisplatin has become the new standard regimen due to a lower toxicity in comparison to the combination of methotrexate , vinblastine , doxorubicin , and cisplatin ( MVAC ) .","paragraph":"<h3><u>[Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?].</u></h3>Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>metastastic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MVAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> For second-line treatment, vinflunine is the only approved therapeutic agent.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"metastastic","start":3,"end":14,"id":1,"ws":true},{"text":"patients","start":15,"end":23,"id":2,"ws":true},{"text":",","start":24,"end":25,"id":3,"ws":true},{"text":"the","start":26,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"of","start":42,"end":44,"id":6,"ws":true},{"text":"gemcitabine","start":45,"end":56,"id":7,"ws":true},{"text":"and","start":57,"end":60,"id":8,"ws":true},{"text":"cisplatin","start":61,"end":70,"id":9,"ws":true},{"text":"has","start":71,"end":74,"id":10,"ws":true},{"text":"become","start":75,"end":81,"id":11,"ws":true},{"text":"the","start":82,"end":85,"id":12,"ws":true},{"text":"new","start":86,"end":89,"id":13,"ws":true},{"text":"standard","start":90,"end":98,"id":14,"ws":true},{"text":"regimen","start":99,"end":106,"id":15,"ws":true},{"text":"due","start":107,"end":110,"id":16,"ws":true},{"text":"to","start":111,"end":113,"id":17,"ws":true},{"text":"a","start":114,"end":115,"id":18,"ws":true},{"text":"lower","start":116,"end":121,"id":19,"ws":true},{"text":"toxicity","start":122,"end":130,"id":20,"ws":true},{"text":"in","start":131,"end":133,"id":21,"ws":true},{"text":"comparison","start":134,"end":144,"id":22,"ws":true},{"text":"to","start":145,"end":147,"id":23,"ws":true},{"text":"the","start":148,"end":151,"id":24,"ws":true},{"text":"combination","start":152,"end":163,"id":25,"ws":true},{"text":"of","start":164,"end":166,"id":26,"ws":true},{"text":"methotrexate","start":167,"end":179,"id":27,"ws":true},{"text":",","start":180,"end":181,"id":28,"ws":true},{"text":"vinblastine","start":182,"end":193,"id":29,"ws":true},{"text":",","start":194,"end":195,"id":30,"ws":true},{"text":"doxorubicin","start":196,"end":207,"id":31,"ws":true},{"text":",","start":208,"end":209,"id":32,"ws":true},{"text":"and","start":210,"end":213,"id":33,"ws":true},{"text":"cisplatin","start":214,"end":223,"id":34,"ws":true},{"text":"(","start":224,"end":225,"id":35,"ws":true},{"text":"MVAC","start":226,"end":230,"id":36,"ws":true},{"text":")","start":231,"end":232,"id":37,"ws":true},{"text":".","start":233,"end":234,"id":38,"ws":false}],"spans":[{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":61,"end":70,"token_start":9,"token_end":9,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},{"start":182,"end":193,"token_start":29,"token_end":29,"label":"DRUG"},{"start":196,"end":207,"token_start":31,"token_end":31,"label":"DRUG"},{"start":214,"end":223,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26077309/","_input_hash":-1827502411,"_task_hash":-95037756,"_session_id":"drug_drug_pilot2_yakir-yakir","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":61,"end":70,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":27,"child":29,"head_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":182,"end":193,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":29,"child":31,"head_span":{"start":182,"end":193,"token_start":29,"token_end":29,"label":"DRUG"},"child_span":{"start":196,"end":207,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":31,"child":34,"head_span":{"start":196,"end":207,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":214,"end":223,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["POS10","NEG10"],"answer":"accept"}
{"text":"In metastastic patients , the combination of gemcitabine and cisplatin has become the new standard regimen due to a lower toxicity in comparison to the combination of methotrexate , vinblastine , doxorubicin , and cisplatin ( MVAC ) .","paragraph":"<h3><u>[Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?].</u></h3>Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>metastastic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MVAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> For second-line treatment, vinflunine is the only approved therapeutic agent.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"metastastic","start":3,"end":14,"id":1,"ws":true},{"text":"patients","start":15,"end":23,"id":2,"ws":true},{"text":",","start":24,"end":25,"id":3,"ws":true},{"text":"the","start":26,"end":29,"id":4,"ws":true},{"text":"combination","start":30,"end":41,"id":5,"ws":true},{"text":"of","start":42,"end":44,"id":6,"ws":true},{"text":"gemcitabine","start":45,"end":56,"id":7,"ws":true},{"text":"and","start":57,"end":60,"id":8,"ws":true},{"text":"cisplatin","start":61,"end":70,"id":9,"ws":true},{"text":"has","start":71,"end":74,"id":10,"ws":true},{"text":"become","start":75,"end":81,"id":11,"ws":true},{"text":"the","start":82,"end":85,"id":12,"ws":true},{"text":"new","start":86,"end":89,"id":13,"ws":true},{"text":"standard","start":90,"end":98,"id":14,"ws":true},{"text":"regimen","start":99,"end":106,"id":15,"ws":true},{"text":"due","start":107,"end":110,"id":16,"ws":true},{"text":"to","start":111,"end":113,"id":17,"ws":true},{"text":"a","start":114,"end":115,"id":18,"ws":true},{"text":"lower","start":116,"end":121,"id":19,"ws":true},{"text":"toxicity","start":122,"end":130,"id":20,"ws":true},{"text":"in","start":131,"end":133,"id":21,"ws":true},{"text":"comparison","start":134,"end":144,"id":22,"ws":true},{"text":"to","start":145,"end":147,"id":23,"ws":true},{"text":"the","start":148,"end":151,"id":24,"ws":true},{"text":"combination","start":152,"end":163,"id":25,"ws":true},{"text":"of","start":164,"end":166,"id":26,"ws":true},{"text":"methotrexate","start":167,"end":179,"id":27,"ws":true},{"text":",","start":180,"end":181,"id":28,"ws":true},{"text":"vinblastine","start":182,"end":193,"id":29,"ws":true},{"text":",","start":194,"end":195,"id":30,"ws":true},{"text":"doxorubicin","start":196,"end":207,"id":31,"ws":true},{"text":",","start":208,"end":209,"id":32,"ws":true},{"text":"and","start":210,"end":213,"id":33,"ws":true},{"text":"cisplatin","start":214,"end":223,"id":34,"ws":true},{"text":"(","start":224,"end":225,"id":35,"ws":true},{"text":"MVAC","start":226,"end":230,"id":36,"ws":true},{"text":")","start":231,"end":232,"id":37,"ws":true},{"text":".","start":233,"end":234,"id":38,"ws":false}],"spans":[{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},{"start":182,"end":193,"token_start":29,"token_end":29,"label":"DRUG"},{"start":196,"end":207,"token_start":31,"token_end":31,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26077309/","_input_hash":-1827502411,"_task_hash":-95037756,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":61,"end":70,"token_start":9,"token_end":9,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":27,"child":29,"head_span":{"start":167,"end":179,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":182,"end":193,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":31,"child":29,"head_span":{"start":196,"end":207,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":182,"end":193,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Rats were distributed into three groups ( n = 5 ) according to the drug studied namely , 50 % enantiomeric excess bupivacaine mixture ( 5 \u03bcg/mL ) ; pancuronium ( 2 \u03bcg/mL ) ; 50 % enantiomeric excess bupivacaine mixture + pancuronium .","paragraph":"<h3><u>Effect of 50% enantiomeric excess bupivacaine mixture combined with pancuronium on neuromuscular transmission in rat phrenic nerve-diaphragm preparation; a pilot study.</u></h3>Local anaesthetics are drugs that are widely used in clinical practice. However, the effects of these drugs on the neuromuscular junction and their influence on the blockade produced by non-depolarising neuromuscular blocking drugs are still under investigation. The aim of this study was to evaluate, in vitro, the influence of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture on neuromuscular transmission and neuromuscular block produced by <b style='color:Tomato;'><i>pancuronium</i></b>. ### methods <b style='color:DodgerBlue;'><i>Rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>distributed</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>namely</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>enantiomeric</i></b> <b style='color:DodgerBlue;'><i>excess</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>\u03bcg/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>\u03bcg/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>enantiomeric</i></b> <b style='color:DodgerBlue;'><i>excess</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The following parameters were evaluated: (1) Effects of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture on membrane potential (MP) and miniature endplate potentials (MEPPs); (2) amplitude of diaphragmatic response before and 60 min after the addition of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture; the degree of neuromuscular block with <b style='color:Tomato;'><i>pancuronium</i></b> and <b style='color:Tomato;'><i>pancuronium</i></b> combined with a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture. ### results A 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture did not alter the amplitude of muscle response (MP) but decreased the frequency and amplitude of MEPP. The block produced by <b style='color:Tomato;'><i>pancuronium</i></b> was potentiated by a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture. ### conclusion A 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture used alone did not affect neuromuscular transmission, but potentiated the neuromuscular block produced by <b style='color:Tomato;'><i>pancuronium</i></b>. No action was shown on the muscle fibre, and alterations on MEPPs demonstrated a presynaptic action.","tokens":[{"text":"Rats","start":0,"end":4,"id":0,"ws":true},{"text":"were","start":5,"end":9,"id":1,"ws":true},{"text":"distributed","start":10,"end":21,"id":2,"ws":true},{"text":"into","start":22,"end":26,"id":3,"ws":true},{"text":"three","start":27,"end":32,"id":4,"ws":true},{"text":"groups","start":33,"end":39,"id":5,"ws":true},{"text":"(","start":40,"end":41,"id":6,"ws":true},{"text":"n","start":42,"end":43,"id":7,"ws":true},{"text":"=","start":44,"end":45,"id":8,"ws":true},{"text":"5","start":46,"end":47,"id":9,"ws":true},{"text":")","start":48,"end":49,"id":10,"ws":true},{"text":"according","start":50,"end":59,"id":11,"ws":true},{"text":"to","start":60,"end":62,"id":12,"ws":true},{"text":"the","start":63,"end":66,"id":13,"ws":true},{"text":"drug","start":67,"end":71,"id":14,"ws":true},{"text":"studied","start":72,"end":79,"id":15,"ws":true},{"text":"namely","start":80,"end":86,"id":16,"ws":true},{"text":",","start":87,"end":88,"id":17,"ws":true},{"text":"50","start":89,"end":91,"id":18,"ws":true},{"text":"%","start":92,"end":93,"id":19,"ws":true},{"text":"enantiomeric","start":94,"end":106,"id":20,"ws":true},{"text":"excess","start":107,"end":113,"id":21,"ws":true},{"text":"bupivacaine","start":114,"end":125,"id":22,"ws":true},{"text":"mixture","start":126,"end":133,"id":23,"ws":true},{"text":"(","start":134,"end":135,"id":24,"ws":true},{"text":"5","start":136,"end":137,"id":25,"ws":true},{"text":"\u03bcg/mL","start":138,"end":143,"id":26,"ws":true},{"text":")","start":144,"end":145,"id":27,"ws":true},{"text":";","start":146,"end":147,"id":28,"ws":true},{"text":"pancuronium","start":148,"end":159,"id":29,"ws":true},{"text":"(","start":160,"end":161,"id":30,"ws":true},{"text":"2","start":162,"end":163,"id":31,"ws":true},{"text":"\u03bcg/mL","start":164,"end":169,"id":32,"ws":true},{"text":")","start":170,"end":171,"id":33,"ws":true},{"text":";","start":172,"end":173,"id":34,"ws":true},{"text":"50","start":174,"end":176,"id":35,"ws":true},{"text":"%","start":177,"end":178,"id":36,"ws":true},{"text":"enantiomeric","start":179,"end":191,"id":37,"ws":true},{"text":"excess","start":192,"end":198,"id":38,"ws":true},{"text":"bupivacaine","start":199,"end":210,"id":39,"ws":true},{"text":"mixture","start":211,"end":218,"id":40,"ws":true},{"text":"+","start":219,"end":220,"id":41,"ws":true},{"text":"pancuronium","start":221,"end":232,"id":42,"ws":true},{"text":".","start":233,"end":234,"id":43,"ws":false}],"spans":[{"start":114,"end":125,"token_start":22,"token_end":22,"label":"DRUG"},{"start":148,"end":159,"token_start":29,"token_end":29,"label":"DRUG"},{"start":199,"end":210,"token_start":39,"token_end":39,"label":"DRUG"},{"start":221,"end":232,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26755834/","_input_hash":-406918301,"_task_hash":-1868675283,"_session_id":"drug_drug_pilot2_yakir-yakir","_view_id":"blocks","relations":[{"head":39,"child":29,"head_span":{"start":199,"end":210,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":148,"end":159,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Rats were distributed into three groups ( n = 5 ) according to the drug studied namely , 50 % enantiomeric excess bupivacaine mixture ( 5 \u03bcg/mL ) ; pancuronium ( 2 \u03bcg/mL ) ; 50 % enantiomeric excess bupivacaine mixture + pancuronium .","paragraph":"<h3><u>Effect of 50% enantiomeric excess bupivacaine mixture combined with pancuronium on neuromuscular transmission in rat phrenic nerve-diaphragm preparation; a pilot study.</u></h3>Local anaesthetics are drugs that are widely used in clinical practice. However, the effects of these drugs on the neuromuscular junction and their influence on the blockade produced by non-depolarising neuromuscular blocking drugs are still under investigation. The aim of this study was to evaluate, in vitro, the influence of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture on neuromuscular transmission and neuromuscular block produced by <b style='color:Tomato;'><i>pancuronium</i></b>. ### methods <b style='color:DodgerBlue;'><i>Rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>distributed</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>namely</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>enantiomeric</i></b> <b style='color:DodgerBlue;'><i>excess</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>\u03bcg/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>\u03bcg/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>enantiomeric</i></b> <b style='color:DodgerBlue;'><i>excess</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The following parameters were evaluated: (1) Effects of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture on membrane potential (MP) and miniature endplate potentials (MEPPs); (2) amplitude of diaphragmatic response before and 60 min after the addition of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture; the degree of neuromuscular block with <b style='color:Tomato;'><i>pancuronium</i></b> and <b style='color:Tomato;'><i>pancuronium</i></b> combined with a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture. ### results A 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture did not alter the amplitude of muscle response (MP) but decreased the frequency and amplitude of MEPP. The block produced by <b style='color:Tomato;'><i>pancuronium</i></b> was potentiated by a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture. ### conclusion A 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture used alone did not affect neuromuscular transmission, but potentiated the neuromuscular block produced by <b style='color:Tomato;'><i>pancuronium</i></b>. No action was shown on the muscle fibre, and alterations on MEPPs demonstrated a presynaptic action.","tokens":[{"text":"Rats","start":0,"end":4,"id":0,"ws":true},{"text":"were","start":5,"end":9,"id":1,"ws":true},{"text":"distributed","start":10,"end":21,"id":2,"ws":true},{"text":"into","start":22,"end":26,"id":3,"ws":true},{"text":"three","start":27,"end":32,"id":4,"ws":true},{"text":"groups","start":33,"end":39,"id":5,"ws":true},{"text":"(","start":40,"end":41,"id":6,"ws":true},{"text":"n","start":42,"end":43,"id":7,"ws":true},{"text":"=","start":44,"end":45,"id":8,"ws":true},{"text":"5","start":46,"end":47,"id":9,"ws":true},{"text":")","start":48,"end":49,"id":10,"ws":true},{"text":"according","start":50,"end":59,"id":11,"ws":true},{"text":"to","start":60,"end":62,"id":12,"ws":true},{"text":"the","start":63,"end":66,"id":13,"ws":true},{"text":"drug","start":67,"end":71,"id":14,"ws":true},{"text":"studied","start":72,"end":79,"id":15,"ws":true},{"text":"namely","start":80,"end":86,"id":16,"ws":true},{"text":",","start":87,"end":88,"id":17,"ws":true},{"text":"50","start":89,"end":91,"id":18,"ws":true},{"text":"%","start":92,"end":93,"id":19,"ws":true},{"text":"enantiomeric","start":94,"end":106,"id":20,"ws":true},{"text":"excess","start":107,"end":113,"id":21,"ws":true},{"text":"bupivacaine","start":114,"end":125,"id":22,"ws":true},{"text":"mixture","start":126,"end":133,"id":23,"ws":true},{"text":"(","start":134,"end":135,"id":24,"ws":true},{"text":"5","start":136,"end":137,"id":25,"ws":true},{"text":"\u03bcg/mL","start":138,"end":143,"id":26,"ws":true},{"text":")","start":144,"end":145,"id":27,"ws":true},{"text":";","start":146,"end":147,"id":28,"ws":true},{"text":"pancuronium","start":148,"end":159,"id":29,"ws":true},{"text":"(","start":160,"end":161,"id":30,"ws":true},{"text":"2","start":162,"end":163,"id":31,"ws":true},{"text":"\u03bcg/mL","start":164,"end":169,"id":32,"ws":true},{"text":")","start":170,"end":171,"id":33,"ws":true},{"text":";","start":172,"end":173,"id":34,"ws":true},{"text":"50","start":174,"end":176,"id":35,"ws":true},{"text":"%","start":177,"end":178,"id":36,"ws":true},{"text":"enantiomeric","start":179,"end":191,"id":37,"ws":true},{"text":"excess","start":192,"end":198,"id":38,"ws":true},{"text":"bupivacaine","start":199,"end":210,"id":39,"ws":true},{"text":"mixture","start":211,"end":218,"id":40,"ws":true},{"text":"+","start":219,"end":220,"id":41,"ws":true},{"text":"pancuronium","start":221,"end":232,"id":42,"ws":true},{"text":".","start":233,"end":234,"id":43,"ws":false}],"spans":[{"start":114,"end":125,"token_start":22,"token_end":22,"label":"DRUG"},{"start":148,"end":159,"token_start":29,"token_end":29,"label":"DRUG"},{"start":199,"end":210,"token_start":39,"token_end":39,"label":"DRUG"},{"start":221,"end":232,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26755834/","_input_hash":-406918301,"_task_hash":-1868675283,"_session_id":"drug_drug_pilot_split2c-yosi","_view_id":"blocks","relations":[{"head":39,"child":42,"head_span":{"start":199,"end":210,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":221,"end":232,"token_start":42,"token_end":42,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
